Press release
Alzheimer's Disease Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron
The Alzheimer's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Alzheimer's Disease Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alzheimer's Disease Market.
Some of the key takeaways from the Alzheimer's Disease Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Alzheimer's Disease treatment therapies with a considerable amount of success over the years.
*
Alzheimer's Disease companies working in the treatment market are Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others, are developing therapies for the Alzheimer's Disease treatment
*
Emerging Alzheimer's Disease therapies in the different phases of clinical trials are- NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others are expected to have a significant impact on the Alzheimer's Disease market in the coming years.
*
In March 2024, MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted novel treatments for debilitating CNS disorders, announced the start of a Phase 1 clinical trial for ML-007/PAC. This is an extended-release fixed-dose combination of the novel investigational muscarinic agonist ML-007 and a precision-matched peripherally active anticholinergic (PAC). The trial builds on findings from three previous Phase 1 trials that assessed the safety and tolerability of ML-007 with PAC. The data from this new trial will guide the dosing regimen for upcoming Phase 2 trials targeting schizophrenia and Alzheimer's disease psychosis. The company plans to start its first Phase 2 trial of ML-007/PAC in schizophrenia later this year.
*
In January 2024, AmyriAD Therapeutics plans to assess its leading Alzheimer's disease small molecule candidate, AD-101, in three forthcoming Phase III studies.
*
In July 2023, Following a conclusion that a confirmatory trial demonstrated clinical benefit, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), intended to treat adult patients with Alzheimer's Disease, to conventional approval. Leqembi is the first amyloid beta-directed antibody for the treatment of Alzheimer's disease to transition from an accelerated approval to a conventional approval.
Alzheimer's Disease Overview
Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects older adults, leading to cognitive decline, memory loss, and changes in behavior and personality. It is the most common cause of dementia, accounting for 60-80% of dementia cases.
Get a Free Sample PDF Report to know more about Alzheimer's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight [https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Alzheimer's Disease Drugs Under Different Phases of Clinical Development Include:
*
NRDN-201: Neurodon
*
ST-501: Sangamo Therapeutics
*
SNK 01: NKGen Biotech
*
ASN51: Asceneuron
*
TB 006: TrueBinding
*
AL002: Alector
*
CT-1812: Cognition Therapeutics
*
Blarcamesine: Anavex Life Sciences
*
E 2814: Eisai Co Ltd
*
Simufilam: Cassava Sciences, Inc.
*
KarXT: Karuna Therapeutics
*
NE3107: BioVie
Alzheimer's Disease Route of Administration
Alzheimer's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Alzheimer's Disease Molecule Type
Alzheimer's Disease Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Alzheimer's Disease Pipeline Therapeutics Assessment
*
Alzheimer's Disease Assessment by Product Type
*
Alzheimer's Disease By Stage and Product Type
*
Alzheimer's Disease Assessment by Route of Administration
*
Alzheimer's Disease By Stage and Route of Administration
*
Alzheimer's Disease Assessment by Molecule Type
*
Alzheimer's Disease by Stage and Molecule Type
DelveInsight's Alzheimer's Disease Report covers around 120+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Alzheimer's Disease product details are provided in the report. Download the Alzheimer's Disease pipeline report to learn more about the emerging Alzheimer's Disease therapies [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Alzheimer's Disease Therapeutics Market include:
Key companies developing therapies for Alzheimer's Disease are - AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Unichem laboratories ltd, Lannett Inc., and others.
Alzheimer's Disease Pipeline Analysis:
The Alzheimer's Disease pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Alzheimer's Disease with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's Disease Treatment.
*
Alzheimer's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Alzheimer's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alzheimer's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Alzheimer's Disease drugs and therapies [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Alzheimer's Disease Pipeline Market Drivers
*
Increase in prevalence of Alzheimer's Disease (AD), rising geriatric population are some of the important factors that are fueling the Alzheimer's Disease Market.
Alzheimer's Disease Pipeline Market Barriers
*
However, clinical trials are more complicated, costly, and slower than trials for other diseases., lack of clear diagnosis and other factors are creating obstacles in the Alzheimer's Disease Market growth.
Scope of Alzheimer's Disease Pipeline Drug Insight
*
Coverage: Global
*
Key Alzheimer's Disease Companies: Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others
*
Key Alzheimer's Disease Therapies: NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others
*
Alzheimer's Disease Therapeutic Assessment: Alzheimer's Disease current marketed and Alzheimer's Disease emerging therapies
*
Alzheimer's Disease Market Dynamics: Alzheimer's Disease market drivers and Alzheimer's Disease market barriers
Request for Sample PDF Report for Alzheimer's Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Alzheimer's Disease Report Introduction
2. Alzheimer's Disease Executive Summary
3. Alzheimer's Disease Overview
4. Alzheimer's Disease- Analytical Perspective In-depth Commercial Assessment
5. Alzheimer's Disease Pipeline Therapeutics
6. Alzheimer's Disease Late Stage Products (Phase II/III)
7. Alzheimer's Disease Mid Stage Products (Phase II)
8. Alzheimer's Disease Early Stage Products (Phase I)
9. Alzheimer's Disease Preclinical Stage Products
10. Alzheimer's Disease Therapeutics Assessment
11. Alzheimer's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Alzheimer's Disease Key Companies
14. Alzheimer's Disease Key Products
15. Alzheimer's Disease Unmet Needs
16 . Alzheimer's Disease Market Drivers and Barriers
17. Alzheimer's Disease Future Perspectives and Conclusion
18. Alzheimer's Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alzheimers-disease-pipeline-drugs-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-neurodon-sangamo-therapeutics-nkgen-biotech-asceneuron]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron here
News-ID: 3527729 • Views: …
More Releases from ABNewswire
Jamaica Welcomes Travelers Back: Five Sandals and Beaches Negril Resort Fully Op …
Sandals Resorts Announces Complete Reopening of Five Jamaica Properties Following October Hurricane
Jamaica's tourism industry is thriving once again as the island destination confirms Five Sandals and Beaches resort properties have fully reopened following Hurricane impacts in October 2025. Travelers planning Caribbean vacations can now book with confidence as Jamaica's world-renowned hospitality and pristine beaches welcome visitors back.
All Five Sandals and Beaches Jamaica Resorts Now Open
Sandals Resorts International has confirmed that…
Asset Optimization Solutions Market to Reach USD 9.6 Billion by 2030, Driven by …
Mordor Intelligence has published a new report on the asset optimization solutions market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Asset Optimization Solutions Market Overview
The asset optimization solutions market reached USD 5.45 billion in 2025 and is projected to grow to USD 9.6 billion by 2030, supported by strong interest in predictive maintenance, cloud-based asset management platforms, and deeper industrial IoT connectivity. As industries modernize equipment management…
Massage Minneapolis by Halo Healing Therapies Co.: Serving Golden Valley, St. Lo …
Halo Healing Therapies Co. in North Loop Minneapolis provides expert therapeutic massage for clients across Golden Valley, St. Louis Park, Hopkins & New Hope. With over 25 years of experience, Halo offers deep tissue, couples, sports, and restorative massage tailored to the active Minneapolis lifestyle. Conveniently located near landmarks like Brookview Park, The West End, Mainstreet Hopkins, and Northwood Park, Halo delivers care that relieves tension, supports recovery, & enhances…
Red Teaming vs Penetration Testing: Understanding the Difference
Image: https://www.abnewswire.com/upload/2025/12/bc1e8a773c50dd0c9305d06207de098f.jpg
The topic of red teaming vs penetration testing often creates confusion among security teams, decision-makers and technical stakeholders. Both approaches aim to uncover weaknesses, yet they work in very different ways. Many organisations rely on one method thinking it covers the role of the other. This misunderstanding can lead to gaps in visibility, unclear expectations and misplaced confidence.
A clearer view of pentest vs red team helps organisations make better…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
